Literature DB >> 29803601

Cognitive Impairment, Vulnerability, and Mortality Post Ischemic Stroke: A Five-Year Follow-Up of the Action on Secondary Prevention Interventions and Rehabilitation in Stroke (ASPIRE-S) Cohort.

Eva Gaynor1, Daniela Rohde2, Margaret Large3, Lisa Mellon4, Patricia Hall3, Linda Brewer5, Orla Conway4, Anne Hickey4, Kathleen Bennett4, Eamon Dolan6, Elizabeth Callaly7, David Williams5.   

Abstract

BACKGROUND: The aim of this study was to examine predictors of mortality in patients 5 years after ischemic stroke, focusing on cognitive impairment, vulnerability, and vascular risk factors assessed at 6 months post stroke.
MATERIALS AND METHODS: Patients from the Action on Secondary Prevention Interventions and Rehabilitation in Stroke (ASPIRE-S) cohort were followed up 5 years post ischemic stroke. Vascular risk factors, cognitive impairment, and vulnerability were assessed at 6 months post stroke. Cognitive impairment was assessed using a cutoff score lower than 26 on the Montreal Cognitive Assessment (MoCA). Vulnerability was defined as a score of 3 or higher on the Vulnerable Elders Scale (VES). Mortality and date of death were ascertained using hospital records, death notifications, and contact with general practitioners. Predictors of mortality were explored using multivariate Cox proportional hazards models. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) are presented.
RESULTS: Sixty-three of 256 patients (24.6%) assessed at 6 months post stroke had died within 5 years. Cognitive impairment (HR [95% CI]: 2.19 [1.42-3.39]), vulnerability (HR [95% CI]: 5.23 [2.92-9.36]), atrial fibrillation (AF) (HR [95% CI]: 2.31 [1.80-2.96]), and dyslipidemia (HR [95% CI]: 1.90 [1.10-3.27]) were associated with increased risk of 5-year mortality. DISCUSSION: Vulnerability, cognitive impairment, AF, and dyslipidemia at 6 months were associated with increased risks of mortality 5 years post ischemic stroke.
CONCLUSION: Identification and management of these risk factors should be emphasized in poststroke care.
Copyright © 2018 National Stroke Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cerebrovascular disorders; cognitive impairment; mortality; secondary prevention; stroke; vulnerability

Mesh:

Year:  2018        PMID: 29803601     DOI: 10.1016/j.jstrokecerebrovasdis.2018.05.002

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  5 in total

1.  The Occurrence and Longitudinal Changes of Cognitive Impairment After Acute Ischemic Stroke.

Authors:  Xiao-Ling Liao; Li-Jun Zuo; Ning Zhang; Yang Yang; Yue-Song Pan; Xiang-Long Xiang; Ling-Yun Chen; Xia Meng; Hao Li; Xing-Quan Zhao; Yi-Long Wang; Chun-Xue Wang; Jiong Shi; Yong-Jun Wang
Journal:  Neuropsychiatr Dis Treat       Date:  2020-03-26       Impact factor: 2.570

2.  The impact of stroke, cognitive function and post-stroke cognitive impairment (PSCI) on healthcare utilisation in Ireland: a cross-sectional nationally representative study.

Authors:  Isabelle Jeffares; Daniela Rohde; Frank Doyle; Frances Horgan; Anne Hickey
Journal:  BMC Health Serv Res       Date:  2022-03-29       Impact factor: 2.655

3.  Montreal Cognitive Assessment of cognitive dysfunction after basal ganglia stroke.

Authors:  Baoye Ye; Dingqun Wei; Lin Pan
Journal:  Acta Neurol Belg       Date:  2022-05-28       Impact factor: 2.471

4.  Comorbidity in patients with first-ever ischemic stroke: Disease patterns and their associations with cognitive and physical function.

Authors:  Rui She; Zhongrui Yan; Yanlei Hao; Zuoji Zhang; Yifeng Du; Yajun Liang; Davide L Vetrano; Joost Dekker; Bo Bai; Joseph T F Lau; Chengxuan Qiu
Journal:  Front Aging Neurosci       Date:  2022-09-09       Impact factor: 5.702

5.  Cognitive impairment and medication adherence post-stroke: A five-year follow-up of the ASPIRE-S cohort.

Authors:  Daniela Rohde; Eva Gaynor; Margaret Large; Lisa Mellon; Kathleen Bennett; David J Williams; Linda Brewer; Patricia Hall; Elizabeth Callaly; Eamon Dolan; Anne Hickey
Journal:  PLoS One       Date:  2019-10-17       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.